secwatch.observer — SEC 8-K summary
======================================

Issuer:     Precipio, Inc. (PRPO)
CIK:        0001043961
Form:       8-K
Filed at:   2026-11-10T21:15:38+00:00
Accession:  0001104659-26-125196
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Precipio Q3-2026 revenue $7.3M, up 8% YoY to a record; Adjusted EBITDA $0.4M, operating cash flow $0.6M
--------------------------------------------------------------------------------

- Revenue $7.3M, up 8% YoY from $6.8M in Q3-2025 and above $7.0M in Q2-2026; product revenue $1.0M (+40% YoY), pathology revenue $6.3M (+5% YoY).
- Adjusted EBITDA $0.4M vs $0.5M in Q3-2025 and $0.4M in Q2-2026; GAAP net income was roughly $0.0M versus a $0.1M net loss a year earlier.
- Cash flow from operations $0.6M; total cash rose $0.5M to over $3.5M at September 30, 2026, versus $2.3M in Q3-2025.
- CEO Ilan Danieli said pathology provides the financial foundation for growth and serves as the clinical validation platform for proprietary diagnostic products.
- Management hosted a shareholder call at 5 PM ET on November 10, 2026; full results are in the Form 10-Q filed the same day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1043961/000110465926125196/0001104659-26-125196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1043961/000110465926125196/tm2629335d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-125196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer